Skip to content

Study · Non-randomized trial · n = 16 · 2011

3 results

Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.

Gamsjaeger S, Buchinger B, Zoehrer R, Phipps R, Klaushofer K, Paschalis EP

Bone27 Aug 2011Cited by 35 (Europe PMC)

PMID21893225 (opens in a new tab)DOI10.1016/j.bone.2011.08.015 (opens in a new tab)PepBankPUB-21893225
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In osteoporotic women previously treated with bisphosphonates, mineral/matrix ratio differed significantly after teriparatide treatment, with direction unreported.

    In plain wordsIn women previously treated with bisphosphonates, bone mineral/matrix ratio changed after teriparatide compared with baseline. The direction was not reported.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedMineral/matrix ratio
    Study

    n = 16

    Comparator
    Before teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment.
    1 context sentence
    Summary · context
    Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed
  2. 02HumanNon-randomized trialEfficacy outcome

    In osteoporotic women previously treated with bisphosphonates, mineral maturity/crystallinity differed significantly after teriparatide treatment, with direction unreported.

    In plain wordsIn women previously treated with bisphosphonates, bone mineral maturity changed after teriparatide compared with baseline. The direction was not reported.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedMineral maturity/crystallinity
    Study

    n = 16

    Comparator
    Before teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment.
    1 context sentence
    Summary · context
    Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed
  3. 03HumanNon-randomized trialEfficacy outcome

    In osteoporotic women previously treated with bisphosphonates, collagen cross-link ratio differed significantly after teriparatide treatment, with direction unreported.

    In plain wordsIn women previously treated with bisphosphonates, collagen cross-link ratio changed after teriparatide compared with baseline. The direction was not reported.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedCollagen cross-link ratio
    Study

    n = 16

    Comparator
    Before teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment.
    1 context sentence
    Summary · context
    Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.